The article entirled, “Development of 166 Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent” published in, pages 28-33, issue 1, vol. 13 of World Journal of Nuclear Medicine[1] is being retracted. It has been found that the concerned article has several overlapping text-sections from a previously published article by same group of authors, entitled, “Production, Quality Control and Biological Evaluation of 166Ho-PDTMP as a Possible Bone Palliation Agent” in pages 719-725, issue 5, vol.16 of Iranian Journal of Basic Medical Sciences[2]. Hence the article is being retracted on the grounds of duplicity of content.
Prof. John Buscombe,
Acting Editor in Chief, WJNM, Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK
References
- 1.Zolghadri S, Jalilian AR, Yousefnia H, Bahrami-Samani A, Ghannadi-Maragheh M. Development of 166 Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent. World J Nucl Med. 2014;13:28–33. doi: 10.4103/1450-1147.138571. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 2.Zolghadri S, Jalilian AR, Naseri Z, et al. Production, Quality Control and Biological Evaluation of 166Ho-PDTMP as a Possible Bone Palliation Agent. Iranian Journal of Basic Medical Sciences. 2013;16(5):719–725. [PMC free article] [PubMed] [Google Scholar]